Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
102
datasets available to search
ShareScore release 0.9.0
Dataset results
102 results for “paroxetine”
Duloxetine Versus Paroxetine for Major Depression
ClinicalTrials.gov study NCT00489775. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees
ClinicalTrials.gov study NCT00261729. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Paroxetine Safety and Efficacy in Rheumatoid Arthritis
ClinicalTrials.gov study NCT06231745. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging (fMRI) Study With Paroxetine Treatment
ClinicalTrials.gov study NCT03894085. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
Objectives: To reanalyse SmithKline Beecham's Study 329 (published by Keller and colleagues in 2001), the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The reanalysis under the restoring invisible and abandoned trials (RIAT) initiative was done to see whether access to and reanalysis of a full dataset from a randomised controlled trial would have clinically relevant implications for evidence based medicine. Design: Double blind randomised placebo controlled trial. Setting: 12 North American academic psychiatry centres, from 20 April 1994 to 15 February 1998. Participants: 275 adolescents with major depression of at least eight weeks in duration. Exclusion criteria included a range of comorbid psychiatric and medical disorders and suicidality. Interventions: Participants were randomised to eight weeks double blind treatment with paroxetine (20-40 mg), imipramine (200-300 mg), or placebo. Main outcome measures: The prespecified primary efficacy variables were change from baseline to the end of the eight week acute treatment phase in total Hamilton depression scale (HAM-D) score and the proportion of responders (HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) at acute endpoint. Prespecified secondary outcomes were changes from baseline to endpoint in depression items in K-SADS-L, clinical global impression, autonomous functioning checklist, self-perception profile, and sickness impact scale; predictors of response; and number of patients who relapse during the maintenance phase. Adverse experiences were to be compared primarily by using descriptive statistics. No coding dictionary was prespecified. Results: The efficacy of paroxetine and imipramine was not statistically or clinically significantly different from placebo for any prespecified primary or secondary efficacy outcome. HAM-D scores decreased by 10.7 (least squares mean) (95% confidence interval 9.1 to 12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to 10.7) points, respectively, for the paroxetine, imipramine and placebo groups (P=0.20). There were clinically significant increases in harms, including suicidal ideation and behaviour and other serious adverse events in the paroxetine group and cardiovascular problems in the imipramine group. Conclusions: Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drugs. Access to primary data from trials has important implications for both clinical practice and research, including that published conclusions about efficacy and safety should not be read as authoritative. The reanalysis of Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base.
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
ClinicalTrials.gov study NCT00560612. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
ClinicalTrials.gov study NCT02932904. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
ClinicalTrials.gov study NCT01916200. IPD Sharing: Not stated. Countries: 0. Publications: 21.
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
ClinicalTrials.gov study NCT00113295. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Concentration-QT Study of Paroxetine in Healthy Adults
ClinicalTrials.gov study NCT06065735. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
ClinicalTrials.gov study NCT00677352. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder
ClinicalTrials.gov study NCT01354314. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions
ClinicalTrials.gov study NCT00841659. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
ClinicalTrials.gov study NCT01987960. IPD Sharing: Not stated. Countries: 9. Publications: 0.
BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder
ClinicalTrials.gov study NCT00839397. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
ClinicalTrials.gov study NCT04311463. IPD Sharing: YES. Countries: 1. Publications: 0.
Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C
ClinicalTrials.gov study NCT00209118. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects
ClinicalTrials.gov study NCT03329573. IPD Sharing: YES. Countries: 1. Publications: 0.
Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
ClinicalTrials.gov study NCT00246441. IPD Sharing: NO. Countries: 1. Publications: 0.
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
ClinicalTrials.gov study NCT00445679. IPD Sharing: Not stated. Countries: 4. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.